Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine for Chorea Associated With Huntington Disease in Canada
NCT06312189Phase 3Enrolling by invitation
- Sponsor
- Neurocrine Biosciences
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valbenazine in Huntington disease (HD), sponsored by Neurocrine Biosciences. Started Apr 2024; status: enrolling by invitation.
02
Drugs
valbenazine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT06312189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06312189.